Optimising operations will help biotechs facilitate movement through critical milestones, avoid delays and help navigate this most difficult program phase. Learn how biotech sponsors can mitigate costly, time-consuming changes by simplifying protocol design in part two of our biotech funding whitepaper series. https://ow.ly/ZyUc50RrXHn
ICON plc’s Post
More Relevant Posts
-
Working on the General Pharma Legislation with EuropaBio - the European Association for Bioindustries team was and still is a valuable experience. 🩺 Proposing a revision of the #GPL after 20-year means a chance to strengthen European competitiveness in the development of cutting-edge therapies and medicines. 🏥 It is necessary to translate #EU market ambitions into concrete actions to reinforce the European biotech ecosystem, promoting innovation and ensuring effective and faster access to medicines. 🧬More #biotech innovations in the EU means more quality for EU healthcare systems. 🔗 If you want to read more about this: https://lnkd.in/d5Hs3f_U
Today Beatrice Rocco is presenting the third Biotech Starter Kit’s factsheet we published this Monday. ➡️ Download our third factsheet at: https://lnkd.in/ejPiuY8m and watch the video below ↓
To view or add a comment, sign in
-
Chicago's climb to 9th place in GEN's Top Biopharma Clusters list underscores our city's growing magnetism for life sciences innovation and company expansion. We're seeing more biotech firms choosing Chicago for their growth, attracted by our world-class research institutions, skilled workforce, and supportive ecosystem. This ranking reflects the hard work of our community and signals to the industry that Chicago is not just a place for startups, but a prime location for established companies to scale and thrive
GEN's 2024 Top Biopharma Clusters list is out, and Chicago has climbed to 9th place, surpassing Seattle. This rise reflects the incredible growth and potential in our biotech ecosystem. Key factors driving our success: Expansion of wet lab developments Landing the CZI expansion Growth in our AI sector While these rankings can be subjective, they're a testament to the hard work and innovation happening right here in Chicago. Read more: https://lnkd.in/gYc5jhyf This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox: https://lnkd.in/g58aVNUw #BiotechChicago #BiopharmaInnovation #LifeSciences #ChicagoTech
To view or add a comment, sign in
-
The biotech funding market is highly competitive, but science that addresses unmet clinical needs and drives progress in key therapeutic areas is still receiving funding. However, the science alone isn’t guaranteed to beat the competition. Read investor insights and best practices to maximise your prospects of securing funding in part one of our two-part biotech funding whitepaper series. https://ow.ly/rQsk50RrQZl
To view or add a comment, sign in
-
-
Thrilled to see Chicago climb to 9th place in GEN’s 2024 Top Biopharma Clusters, surpassing Seattle! Key drivers of our rise: - Growth in wet lab developments - Chan Zuckerberg Initiative expansion - Booming AI sector As venture capital markets recover, attracting more investment will be crucial to sustaining this momentum. Stay tuned for the Illinois Biotechnology Innovation Organization (iBIO) economic report for deeper insights into our biopharma growth. #Biopharma #Chicago #Innovation #AI #Investment #GENrankings Read more on iBIO NewsBrief.
GEN's 2024 Top Biopharma Clusters list is out, and Chicago has climbed to 9th place, surpassing Seattle. This rise reflects the incredible growth and potential in our biotech ecosystem. Key factors driving our success: Expansion of wet lab developments Landing the CZI expansion Growth in our AI sector While these rankings can be subjective, they're a testament to the hard work and innovation happening right here in Chicago. Read more: https://lnkd.in/gYc5jhyf This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox: https://lnkd.in/g58aVNUw #BiotechChicago #BiopharmaInnovation #LifeSciences #ChicagoTech
To view or add a comment, sign in
-
Bonum Therapeutics' John Mulligan, Ph.D. drops a gold nugget of wisdom in today's #BusinessOfBiotech for anyone who has to make executive decisions. In other words, that's just about everybody. When prioritizing tasks, you generally have three types. Low complexity/high value — these are rare. High complexity/low value — these are abundant. High complexity/high value — these are the Goldilocks tasks. I don't know about you, but I can get confused by those abundant high-complexity/low-value tasks. They're easy to spot but sneaky about hiding their payout value. I bet discerning the difference saves a ton of time and boosts productivity.
To view or add a comment, sign in
-
In this upcoming webinar, Cook MyoSite's Adam Hostetler will divulge industry secrets for fostering successful biotech partnerships, detailing the importance of defining mutual goals, data sharing guidelines and more. Register now >>> https://hubs.ly/Q02xfyS80
Best practices to maximize strategic partnerships in regenerative medicine
To view or add a comment, sign in
-
Navigate the ins and outs of strategic industry partnerships with Adam Hostetler, Director of Business Operations at Cook MyoSite, in this upcoming webinar! Register for free and uncover key strategies and best practices for developing a successful biotech partnership >>> https://hubs.ly/Q02xfyJR0
Best practices to maximize strategic partnerships in regenerative medicine
To view or add a comment, sign in
-
The overall picture of the Swiss biotech industry is quite positive. The Swiss Biotech Report recently published provides an analysis of the 2023 biotech funding as well as other key ratios and statistics: https://lnkd.in/dGSvh2d With Swiss Biotech Association https://lnkd.in/dAtS7hyU
To view or add a comment, sign in
-
R&D, Drug Development & Medical Affairs, Market Access Global Clinical Studies and Product Lifecycle Management, RA, Board of Directors, International Speaker, Development Programs, Strategic Leadership.
Not easy to start a new company
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
argenx CEO Tim Van Hauwermeiren
To view or add a comment, sign in
-
In the latest episode of Exceptional Leaders / Exceptional Ideas, our CEO Tim Van Hauwermeiren discusses his entrepreneurial journey, navigating the launch of argenx, and our approach to developing innovative treatments for autoimmune conditions. Watch the full episode below.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
argenx CEO Tim Van Hauwermeiren
To view or add a comment, sign in
Felix Perez, CEO Research Director
3moAbsolutely crucial insights for biotech sponsors navigating critical milestones! Simplifying protocol design can be a game-changer in avoiding delays and optimizing operations. Looking forward to diving into part two of the whitepaper series. #Biotech #ProtocolDesign